Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Avrobio Fell as Much as 16.4% Today

By Maxx Chatsko - Feb 13, 2020 at 2:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small-cap biopharmaceutical company announced a public stock offering.

What happened

Shares of Avrobio (AVRO -2.69%) fell as much as 16.4% today after the company announced and priced a public offering of common stock. The small-cap biopharmaceutical company will raise up to $115 million in gross proceeds by selling up to 5 million shares at $23 apiece. 

The move wisely takes advantage of a soaring stock price, which was approaching a one-year high. The new funds will pad a balance sheet that sported $206 million in cash at the end of September and support ongoing development of the company's gene therapy drug candidates.

As of 1:13 p.m. EST, the pharma stock had settled to a 15.2% loss.

Multiple arrows with a declining slope drawn on a chalkboard.

Image source: Getty Images.

So what

Avrobio has three gene therapy drug candidates in early-stage development. Given Avrobio's market valuation of only $713 million, investors appear to be waiting for the company to demonstrate real-world success before they get too carried away. 

That's not too surprising considering the early-stage nature of the drug pipeline, but Avrobio thinks it will eventually turn heads on Wall Street thanks to its technology platform. The company has designed a novel lentiviral vector (LV2) -- a vector is the vehicle used to deliver the therapeutic payload into a patient's cells -- using its plato platform that is expected to boast several advantages over prior-generation vectors. 

For example, LV2 is expected to have greater efficacy at making genetic changes, allow for individualized conditioning and dosing regimens, have improved shelf life, and benefit from improved manufacturing processes. The first patient was dosed with a plato vector in late December. All new patients receiving treatment in two of the company's three ongoing clinical programs will receive plato vectors going forward.

Now what

Avrobio should now have plenty of cash to support the continued development of its three experimental gene therapies throughout 2020. If early results from individuals dosed with drug candidates designed using the plato platform show promise, then Wall Street might take notice of the small-cap biopharmaceutical company. Until then, investors seem content to wait and see how things play out.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AVROBIO, Inc. Stock Quote
AVROBIO, Inc.
AVRO
$0.78 (-2.69%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.